ReviewCurrent diabetes reports2004
Waiting to inhale: noninjectable insulin, are we there yet?
Review in Current diabetes reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subcutaneous injection has been the only route of insulin administration for patients with type 1 or type 2 diabetes for the past 80 years. Although research and development in this time has improved the insulin treatments themselves, it is only now that alternative routes of insulin administration are becoming viable. Many avenues of insulin administration have been explored, including oral, buccal, and pulmonary routes. However, these methods of noninvasive insulin delivery are not free from difficulties and only preliminary data are available for oral insulin pills and buccal insulin sprays. The most promising alternative route of delivery appears to be inhaled insulin and two devices are already in phase III testing. Nevertheless, inhaled insulin devices will still have to overcome some problems and recent studies show that these challenges are currently being confronted. It appears that years of research into noninvasive methods of insulin administration are close to fruition and this review outlines the most recent findings in this area.
Indexed as
Identifiers
15461897What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.